Dr Liz Dallimore is the CEO and Managing Director of Argenica Therapeutics (ASX:AGN), a clinical stage drug development company developing therapies to treat stroke and other neurological conditions. Dr Dallimore led the company’s IPO in June 2021 and has advanced the company from preclinical research and into a Phase 2 clinical trial in stroke patients. Dr Dallimore is also the co-founder and Executive Chairman of medical device company Inspiring Holdings, a company developing devices for improved inhaled drug delivery.

Dr Dallimore has deep experience in both biotechnology and management consulting with over 20 years’ experience across Australia and the UK. She has held senior roles in management consulting as KPMG’s National Director of Research Engagement and Commercialisation, structuring technology commercialisation deals across a range of sectors. Prior to this she held senior roles with Ernst & Young and PricewaterhouseCoopers.

Dr Dallimore is also a non-executive director of the Chamber of Commerce and Industry WA, Industry Advisor to the Telethon Kids Institute’s Innovation and Commercialisation Committee and Curtin University’s Industry Advisory Board for the School of Electrical Engineering, Computing and Mathematical Science. Dr Dallimore also has the privilege of sitting on the Stan Perron Charitable Foundation’s Health Research Advisory Panel advising on child health research funding.

Dr Dallimore holds a PhD in Neuroscience jointly completed at Oxford University and the University of Western Australia, an MBA from the Australian Graduate School of Management, and is a Member of the Australian Institute of Company Directors.